Kazia Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Für Kazia Therapeutics wird ein Gewinn- und Umsatzwachstum von 54.8% bzw. 69.8% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 64.4% pro Jahr steigen soll.

Wichtige Informationen

54.8%

Wachstumsrate der Gewinne

64.40%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	25.2%
Wachstumsrate der Einnahmen	69.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	01 Jul 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Seeking Alpha • Jul 06

Kazia gains on FDA’s rare pediatric disease designation for childhood cancer therapy

The ADRs of Australian biotech Kazia Therapeutics (NASDAQ:KZIA) gained 8% Wednesday after the company announced that the U.S. Food and Drug Administration (FDA) granted the Rare Pediatric Disease Designation for an experimental therapy targeted at a form of childhood cancer. Paxalisib a brain-penetrant inhibitor received the designation as a treatment for atypical rhabdoid / teratoid tumors (AT/RT), a rare and highly aggressive childhood brain cancer, Kazia (KZIA) said in a press release. In awarding the RPD tag, the federal agency picks drug candidates targeted at serious and life-threatening diseases affecting less than 200K individuals in the U.S. with a primary impact on children aged 18 years or younger. If a drug with a rare pediatric disease designation wins FDA approval, the sponsor of its marketing application is entitled to receive a Priority Review Voucher (PRV) from the regulator. The PRVs valued at more than $100M historically, can be redeemed to receive a priority review for any subsequent marketing application, or it can be sold. In June, Kazia (KZIA) announced that the FDA awarded orphan drug designation for Paxalisib for the same condition.

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:KZIA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (AUD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2029	18	-27	N/A	-26	2
6/30/2028	0	-35	N/A	-26	2
6/30/2027	0	-30	N/A	-29	2
6/30/2026	0	-26	N/A	-28	2
12/31/2025	2	-23	-14	-14	N/A
9/30/2025	2	-22	-14	-14	N/A
6/30/2025	2	-21	-13	-13	N/A
3/31/2025	2	-25	-12	-12	N/A
12/31/2024	3	-28	-12	-12	N/A
9/30/2024	2	-28	-11	-11	N/A
6/30/2024	2	-27	-10	-10	N/A
3/31/2024	1	-21	-11	-11	N/A
12/31/2023	0	-16	-13	-13	N/A
9/30/2023	0	-18	-14	-14	N/A
6/30/2023	0	-20	-15	-15	N/A
3/31/2023	0	-23	-18	-18	N/A
12/31/2022	N/A	-25	-20	-20	N/A
9/30/2022	0	-25	-21	-21	N/A
6/30/2022	0	-25	-23	-23	N/A
3/31/2022	8	-20	-15	-15	N/A
12/31/2021	15	-15	-8	-8	N/A
9/30/2021	15	-12	-9	-9	N/A
6/30/2021	15	-8	-9	-9	N/A
3/31/2021	8	-11	-14	-14	N/A
12/31/2020	0	-13	-18	-18	N/A
9/30/2020	1	-13	-14	-14	N/A
6/30/2020	1	-12	-9	-9	N/A
3/31/2020	1	-11	-7	-7	N/A
12/31/2019	1	-10	-5	-5	N/A
9/30/2019	1	-10	N/A	-6	N/A
6/30/2019	1	-10	N/A	-7	N/A
3/31/2019	2	-11	N/A	-6	N/A
12/31/2018	2	-12	N/A	-5	N/A
9/30/2018	3	-9	N/A	-7	N/A
6/30/2018	3	-6	N/A	-9	N/A
3/31/2018	4	-6	N/A	-10	N/A
12/31/2017	6	-6	N/A	-12	N/A
9/30/2017	7	-8	N/A	-12	N/A
6/30/2017	9	-11	N/A	-11	N/A
3/31/2017	7	-12	N/A	-12	N/A
12/31/2016	5	-12	N/A	-12	N/A
9/30/2016	4	-12	N/A	-12	N/A
6/30/2016	3	-12	N/A	-12	N/A
3/31/2016	3	-10	N/A	-12	N/A
12/31/2015	3	-9	N/A	-12	N/A
9/30/2015	2	-8	N/A	-9	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: KZIA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: KZIA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: KZIA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: KZIADie Einnahmen des Unternehmens (69.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (12.8% pro Jahr).

Hohe Wachstumseinnahmen: KZIADie Einnahmen des Unternehmens (69.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von KZIA in 3 Jahren voraussichtlich hoch sein wird

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/07/08 23:22
Aktienkurs zum Tagesende	2026/07/08 00:00
Gewinne	2025/12/31
Jährliche Einnahmen	2025/06/30

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Kazia Therapeutics Limited wird von 6 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Kambiz Yazdi	BTIG
Soo Romanoff	Edison Investment Research
Sean Lee	H.C. Wainwright & Co.

Kazia Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates upgraded to AU$0.016 loss

Recent updates

New major risk - Revenue and earnings growth

Kazia Therapeutics Limited Announces Appointment of James Levine to Chief Financial Officer, Effective June 1, 2026

Consensus EPS estimates upgraded to AU$0.016 loss

Kazia Therapeutics Expands Ongoing Phase 1B Trial of Paxalisib in Advanced Breast Cancer

Kazia Therapeutics Limited Appoints Dr. Sudha Rao as Chief Scientific Officer

Kazia Therapeutics Limited Expands Oncology Platform with First-In-Class SETDB1 Inhibitor Drug Development Platform

First half 2026 earnings released: AU$4.02 loss per share (vs AU$12.29 loss in 1H 2025)

New major risk - Negative shareholders equity

Kazia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of $100 million.

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1B Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations Including TNBC and HER2+

Kazia Therapeutics Limited announced that it expects to receive $50.000896 million in funding from ADAR1 Capital Management, LLC, Ikarian Capital, LLC, Stonepine Capital Management LLC, Velan Capital Partners LP, Revach Capital Management LLC

Kazia Therapeutics Limited Achieves Initial iCR (Immune- Complete Response) in Metastatic TNBC and Delivers Fourth Quarter Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy

Kazia Therapeutics Limited announced delayed 20-F filing

Kazia Therapeutics Limited Plans to Request Type C Meeting with U.S. Food & Drug Administration to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA Initiative Project FrontRunner

Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic Tnbc Patient Treatment with Paxalisib-Immunotherapy Regimen

Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage Iv Her2-Positive Breast Cancer with Paxalisib Monotherapy

Kazia Therapeutics Limited announced that it expects to receive $2.049992 million in funding

Kazia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of $1.906196 million.

Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen Achieves >50% Reduction in Circulating Tumor Cells in Phase 1B Trial

First half 2025 earnings released: AU$12.29 loss per share (vs AU$18.40 loss in 1H 2024)

Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer

Kazia Therapeutics Limited Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer

New minor risk - Financial data availability

High number of new and inexperienced directors

Kazia Therapeutics Limited Announces the Launch of A Groundbreaking Trial with Paxalisib in Combination with Immunotherapy in Women with Advanced Breast Cancer

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of $1.999922 million.

Kazia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of $2 million.

Kazia Therapeutics Limited Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA

Kazia Therapeutics Limited Announces to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium

Kazia Therapeutics Limited Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

Kazia Therapeutics Limited announced delayed 20-F filing

New minor risk - Financial data availability

Kazia Therapeutics Announces Presentation of Evt801 Clinical Data At 15 Biennial Ovarian Cancer Research Symposium

New major risk - Market cap size

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of $10 million.

Kazia Therapeutics Limited Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

Kazia Therapeutics Limited Reports Successful Stage 1 Completion of the EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients

Kazia Therapeutics Limited announced that it expects to receive $15 million in funding from Alumni Capital LP

New major risk - Share price stability

New major risk - Financial position

New minor risk - Financial data availability

Kazia Therapeutics Limited Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

Kazia Therapeutics Limited Announces Appointment of Board Members

Kazia Therapeutics Limited Announces Executive Changes

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of $1.981756 million.

Kazia Therapeutics Announces Receipt of Nasdaq Minimum Bid Notification

High number of new and inexperienced directors

Kazia Therapeutics Provides Preliminary Update from Ongoing Phase 2 Study of Paxalisib in Primary Cns Lymphoma

Kazia Therapeutics Limited Announces Clinical Data At ESMO 2023 from Ongoing Phase 1 ESMO Study

Kazia Therapeutics Limited Announces Acceptance of Late-Breaking Abstracts and Oral Presentation of Pnoc022 Clinical Data At 2023 Society for Neuro-Oncology Annual Meeting

Kazia Therapeutics Limited, Annual General Meeting, Nov 08, 2023

Kazia Therapeutics Limited Announces Change to Board of Directors

Kazia Therapeutics Limited Appoints John Friend as Managing Director

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.5 million.

Kazia Therapeutics Limited Receives Fast Track Designation from FDA for Treatment of Solid Tumor Brain Metastases Harboring PI3K Pathway Mutations in Combination with Radiation Therapy

Kazia Therapeutics Limited Announces Phase II Clinical Study to Investigate Paxalisib in Recurrent/Progressive IDH-Mutant Grade 2 & 3 Glioma

Kazia Therapeutics Limited Appoints Ms. Ebru Davidson to its Board

Kazia gains on FDA’s rare pediatric disease designation for childhood cancer therapy

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Datenquellen

Analysemodell und Schneeflocke

Metriken für Industrie und Sektor

Analysten-Quellen